Literature DB >> 23677024

Does Antiretroviral Therapy Interfere With the Treatment of Trichomonas vaginalis Among HIV+ Women?

Patricia Kissinger, Alys Adamski, Rebecca A Clark, Leandro Mena, Judy Levison, David H Martin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23677024      PMCID： PMC3755772          DOI： 10.1097/OLQ.0b013e31829335fe

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN： 0148-5717            Impact factor:   2.830


× No keyword cloud information.
  10 in total

1.  A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women.

Authors:  Jane R Schwebke; Renee A Desmond
Journal:  Sex Transm Dis       Date:  2010-06       Impact factor: 2.830

2.  The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women.

Authors:  Megan Gatski; David H Martin; Judy Levison; Leandro Mena; Rebecca A Clark; Mary Murphy; Harold Henderson; Norine Schmidt; Patricia Kissinger
Journal:  Sex Transm Infect       Date:  2011-01-29       Impact factor: 3.519

3.  Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis.

Authors:  L duBouchet; M R Spence; M F Rein; M R Danzig; W M McCormack
Journal:  Sex Transm Dis       Date:  1997-03       Impact factor: 2.830

4.  A randomized treatment trial: single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women.

Authors:  Patricia Kissinger; Leandro Mena; Judy Levison; Rebecca A Clark; Megan Gatski; Harold Henderson; Norine Schmidt; Susan L Rosenthal; Leann Myers; David H Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2010-12-15       Impact factor: 3.731

5.  Trichomonas vaginalis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population.

Authors:  Jamie W Krashin; Emilia H Koumans; Ayanna C Bradshaw-Sydnor; Jim R Braxton; W Evan Secor; Mary K Sawyer; Lauri E Markowitz
Journal:  Sex Transm Dis       Date:  2010-07       Impact factor: 2.830

6.  Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women.

Authors:  L M Niccolai; J J Kopicko; A Kassie; H Petros; R A Clark; P Kissinger
Journal:  Sex Transm Dis       Date:  2000-05       Impact factor: 2.830

7.  The minimum single oral metronidazole dose for treating trichomoniasis: a randomized, blinded study.

Authors:  M R Spence; T S Harwell; M C Davies; J L Smith
Journal:  Obstet Gynecol       Date:  1997-05       Impact factor: 7.661

8.  Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women.

Authors:  Patricia Kissinger; W Evan Secor; Jami S Leichliter; Rebecca A Clark; Norine Schmidt; Erink Curtin; David H Martin
Journal:  Clin Infect Dis       Date:  2008-04-01       Impact factor: 9.079

9.  Trichomonas vaginalis among HIV-Infected women: are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity?

Authors:  Manya Magnus; Rebecca Clark; Leann Myers; Thomas Farley; Patricia J Kissinger
Journal:  Sex Transm Dis       Date:  2003-11       Impact factor: 2.830

10.  A double-blind placebo-controlled trial of single-dose intravaginal versus single-dose oral metronidazole in the treatment of trichomonal vaginitis.

Authors:  B H Tidwell; W B Lushbaugh; M D Laughlin; J D Cleary; R W Finley
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226
  10 in total
  2 in total

1.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

Review 2.  Trichomoniasis and HIV interactions: a review.

Authors:  Patricia Kissinger; Alys Adamski
Journal:  Sex Transm Infect       Date:  2013-04-20       Impact factor: 3.519
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.